Catalyst Edge · Scanner · Tickers · PEN
CATALYST DOSSIER · UPDATED 2026-09-22

$PEN

Unclassified · convergence · conviction
Convergence Score
Conviction
Signals Firing
0
Quick tools:🃏 Swipe deck🎯 Today verdict

Price & Live Quote

Loading live quote & chart…

Practice trade tools

Build a reference frame, save a practice trade, or preview a draft. No brokerage order is placed.

Paper trade unavailable: missing risk-bounded frame

Reference only. Not financial advice. No brokerage order is placed.

Why $PEN?

PEN -13 AVOID biotech

Quantitative

  • Revenue (CY2026Q1): $374.8M (+15.6% YoY)
  • Net Income (CY2026Q1): $32.6M (-16.9% YoY)
  • Net Margin (CY2026Q2): 8.9%

Catalysts

  • Multi-spoke convergence: 5 convergent signals fired: auto_macro_move_index, auto_macro_nbp_fx, auto_macro_ofr_fsi, auto_macro_options_gex, auto_macro_regime_classifier

Risks

  • Position-sizing discipline: Conviction AVOID (-13 score) — size accordingly; no specific catalyst-fade risk flagged

Bear case

  • Multiple compression: If breadth deteriorates, biotech-wide multiples re-rate lower regardless of pick-specific thesis

Sympathy basket (cerebro)

  • RBLX via tech r=+0.69 sympathetic (score 18)
  • RDDT via tech r=+0.69 sympathetic (score 17)
  • TU via comms r=-0.68 divergent (score 30)
  • VEON via comms r=-0.68 divergent (score 12)
  • OMH via real_estate r=-0.53 divergent (score 21)
  • FREI via real_estate r=-0.53 divergent (score 7)

Signals Firing

No active signals this cycle.
Each tag is a spoke that flagged this ticker today. Weights tuned weekly against published outcomes.

Earnings Catalyst

No recent earnings event.

Auto-generated from public filings + tier-1 wires. Catalyst Edge publishes its picks and its losses — see the trust report and methodology. Not financial advice. Confirm independently before trading.